SARS-CoV-2 strain

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition Alpha antibodies antibody approved B.1.1.7 B.1.351 Beta Beta variant binding cellular response Cellular responses Chilean circulating variant clinical trial concern CoronaVac coronavirus D614G death rate Delta delta variant described detect dose elicited ELISPOT enrolled evaluate evaluated Gamma genetic difference genetic differences geometric mean Geometric means house human ACE2 receptor immune response immunization immunization schedule immunization schedules immunized immunogenic in-house ELISA inactivated induced Infection interferon interferon-γ-secreting T cell interferon-γ-secreting T cells Lineage microneutralization neutralization neutralize Neutralizing antibodies neutralizing antibody neutralizing capacity P.1 pandemic PBMC PBMCs Phase 3 phase 3 clinical trial promote Protective RBD Receptor binding domain Recognition reduced respiratory responsible Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants secreted secretion Seropositivity severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown significant differences spike stimulate subject T cell immunity T cells tested the RBD the SARS-CoV-2 the vaccine titers Vaccine variant variants variants of concern virus Volunteer volunteers were used Wuhan Wuhan, China
[DOI] 10.3389/fimmu.2021.747830 PMC 바로가기 [Article Type] Clinical Trial